EP0154780B1 - Composés antibactériens quinoléiques - Google Patents
Composés antibactériens quinoléiques Download PDFInfo
- Publication number
- EP0154780B1 EP0154780B1 EP85100767A EP85100767A EP0154780B1 EP 0154780 B1 EP0154780 B1 EP 0154780B1 EP 85100767 A EP85100767 A EP 85100767A EP 85100767 A EP85100767 A EP 85100767A EP 0154780 B1 EP0154780 B1 EP 0154780B1
- Authority
- EP
- European Patent Office
- Prior art keywords
- compound
- alkyl
- hydrogen
- quinoline
- oxo
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
- C07D215/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3 with oxygen atoms in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Definitions
- This invention relates to new quinoline derivatives having antibacterial properties, compositions containing the new quinoline derivatives and methods of treating mammalian patients with the new quinoline derivatives.
- quinoline derivatives are disclosed in EP-A-131 839, US ⁇ A ⁇ 4,017,622 or in Progress in Drug Research 21/12977) 12-14, which however are not 6,8-difluoro 1-phenyl substituted quinolines.
- GB ⁇ A ⁇ 2 094 305 discloses quinoline derivatives having an ethyl substituent in the 1-position while GB ⁇ A ⁇ 1 147 336 discloses quinoline derivatives which are not 6,8-difluoro substituted.
- This invention relates to novel antibacterial agents having the formula: wherein R 1 is hydrogen or a carboxy protecting group; R is phenyl having the formula: wherein R 2 is methylenedioxy or one or two substituents independently selected from hydrogen, halogen, nitro, carboxyl cyano, C 1 to C 6 alkyl, hydroxy-substituted C 1 to C 6 alkyl, halo substituted C 1 to C 6 alkyl, a substituent having the formula wherein -Y- is ⁇ O ⁇ or ⁇ S ⁇ and R 3 is hydrogen or C 1 to C 6 alkyl, and a substituent of the formula: wherein R 4 and R 5 are independently hydrogen or C, to C 6 alkyl; and, Z is selected from 1) an aliphatic heterocyclic ring having the structure: wherein R 8 is ⁇ CH 2 ⁇ CH 2 ⁇ or ⁇ CH 2 ⁇ R 9 ⁇ CH 2 ⁇ wherein R 9 is selected from the group consisting of ⁇ S, -0-, -NH-
- halogen refers to chloro, bromo, fluoro and iodo groups
- C 1 to C 6 alkyl refers to lower alkyl groups including methyl, ethyl, propyl, isopropyl and butyl.
- R 2 can be C, to C 6 straight or branched alkyl as well as hydroxy and halo- substituted derivatives thereof.
- groups include a chloromethyl group, a chloroethyl group, a chloropropyl group, a hydroxyethyl group, and a trifluoromethyl group.
- R 2 can also be a group of the formula -Y-R 3 .
- Representative groups of this type include a hydroxy group, a mercapto group, a lower alkoxy group, such as methoxy, ethoxy, propoxy, as well as the thio analogs thereof, namely a methylmercapto group, and an ethylmercapto group.
- carboxy-protecting group refers to and includes the residue of a carboxylic acid ester group.
- carboxy-protecting groups are well known to those skilled in the art, having been extensively used in the protection of carboxyl groups in the penicillin and cephalosporin fields, as described in U.S. Patent Nos. 3,840,556 and 3,719,667. In general, such carboxy-protecting groups can be relatively easily cleaved to yield the corresponding free carboxy group.
- protecting groups include C 1 ⁇ C 8 alkyl (e.g., methyl, ethyl, tertiary butyl), benzyl and substituted derivatives thereof such as alkoxy and nitrobenzyl groups; also suitable are acyl groups such as pivaloyloxymethyl groups.
- aliphatic heterocyclic groups represented by Z are piperazinyl groups, 4-acylpiperazinyl groups, piperidinyl groups, pyrrolidinyl groups, morpholino groups, thiomorpholino groups and homopiperazinyl groups (i.e., hexahydro-1-H-1,4-diazepinyl).
- pharmaceutically acceptable salts of the foregoing compounds.
- pharmaceutically acceptable salts refers to non-toxic acid addition salts and alkaline earth metal salts of the compounds of formula I.
- the salts can be prepared in situ during the final isolation and purification of the compounds of formula I, or separately by reacting the free base or acid functions with a suitable organic acid or base.
- Representative acid addition salts include the hydrochloride, hydrobromide, sulphate, bisulphate, acetate, oxalate, valerate, oleate, palmitate, stearate, laurate, borate, benzoate, lactate, phosphate, tosylate, mesylate, citrate, maleate, fumarate, succinate, tartrate, glucoheptonate, lactobionate, lauryl sulfate salts and the like.
- Representative alkali or alkaline earth metal salts include the sodium, calcium, potassium and magnesium salts. It has been found that the compounds of the present invention possess antibacterial activity against a wide spectrum of gram positive and gram negative bacteria, as well as enterobacteria. The compounds of the invention are therefor useful in the antibiotic treatment of susceptible bacterial infections in both humans and animals. In addition, the compounds, by reason of their in vitro activity, may be used in scrub solutions for surface inhibition of bacterial growth.
- Susceptible organisms generally include those gram positive and gram negative, aerobic and anaerobic organisms whose growth can be inhibited by the compounds of the invention such as Staphylococcus, Lactobacillus, Streptococcus, Sarcina, Escherichia, Enterobacter, Klebsiella, Pseudomonas, Acinetobacter, Proteus, Citrobacter, Nisseria, Baccillus, Bacteroides, Peptococcus, Clostridium, Salmonella, Shiqella, Serratia, Haemophilus, Brucella, and other organisms.
- the compounds of the invention exhibit increased and improved solubility characteristics as compared with prior quinoline-3-carboxylic acid compounds in the art.
- the compounds of Formula I may also be formulated into compositions together with pharmaceutically acceptable carriers for parenteral injection, for oral administration in solid or liquid form, for rectal administration, and the like.
- compositions according to the invention for parenteral injection may comprise pharmaceutically acceptable sterile aqueous or nonaqueous solutions, suspensions or emulsions.
- suitable nonaqueous carriers, diluents, solvents or vehicles include propylene glycol, polyethylene glycol, vegetable oils, such as olive oil, and injectable organic esters such as ethyl oleate.
- Such compositions may also contain adjuvants such as preserving, wetting, emulsifying, and dispersing agents. They may be sterilized, for example, by filtration through a bacteria-retaining filter, or by incorporating sterilizing agents into the compositions. They can also be manufactured in the form of sterile solid compositions which can be dissolved in sterile water, or some other sterile injectable medium immediately before use.
- Solid dosage forms for oral administration include capsules, tablets, pills, powders and granules.
- the active compound is admixed with at least one inert diluent such as sucrose, lactose or starch.
- Such dosage forms can also comprise, as is normal practice, additional substances other than diluents, e.g., lubricating agents such as magnesium stearate.
- the dosage forms may also comprise buffering agents. Tablets and pills can additionally be prepared with enteric coatings.
- Liquid dosage forms for oral administration include pharmaceutically acceptable emulsions, solutions, suspensions, syrups and elixers containing inert diluents commonly used in the art, such as water. Besides such inert diluents, compositions can also include adjuvants, such as wetting agents, emulsifying and suspending agents, and sweetening, flavoring and perfuming agents.
- compositions for rectal administration are preferably suppositories which may contain, in addition to the active substance, excipients such as cocoa butter or a suppository wax.
- Actual dosage levels of active ingredient in the compositions of the invention may be varied so as to obtain an amount of active ingredient effective to achieve antibacterial activity in accordance with the desired method of administration.
- the selected dosage level therefore depends upon the nature of the active compound administered, the route of administration, the desired duration of treatment and other factors.
- daily dosage levels of the compounds of Formula I of about 0.1 to about 750, more preferably about 0.25 to about 500 and most preferably about 0.5 to about 300 mg. of active ingredient per kg. of body weight are effective when administered orally to a mammalian patient suffering from an infection caused by a susceptible organism.
- the daily dose may be divided into multiple doses for administration, e.g., two to four times per day.
- the title compound is prepared as follows: To a suspension of 5 g. of the product of 1 (d) in 40 ml. 1-methyl-2-pyrrolidinone at 120° under nitrogen atmosphere is added 9.5 ml. of N-carboethoxy- piperazine. After 20 hours, the solvent is removed under reduced pressure, and the residue is suspended in 150 ml. ethanol and refluxed for hour. The reaction mixture is then cooled and filtered. The resulting solid is washed with cold ethanol and water to obtain 1-phenyl-6,8-difluoro-7-(4-carboethoxy-l-piperazinyl)-1,4-dihydro-4-oxo-quinoline-3-carboxylic acid.
- the ethyl-2,3,4,5-tetrafluorobenzoyl acetate is prepared as follows: To a solution of 39 g. of 2,3,4,5-tetrafluorobenzoic acid in 200 ml. of methylene chloride are added 40 ml. of thionyl chloride and 2 drops of dimethylformamide. After refluxing for 3 hours, the reaction mixture is evaporated to dryness to give the corresponding acid chloride.
- Example 1 The procedure of Example 1 is repeated replacing piperazine in Example 1(e) with N-methylpiperazine to obtain I-phenyl-6,8-difluoro-1,4-dihydro-4-oxo-7-(1-(4-methyl)piperazinyl)-quinoline-3-carboxylic acid and its hydrochloride salt.
- Example 1 In the described fashion as Example 1, replacing piperazine in Example 1(e) with pyrrolidine, one can obtain 1-phenyl-6,8-difluoro-1,4-dihydro-4-oxo-7-(1-pyrrolidinyl)quinoline-3-carboxylic acid in good yield.
- Example 1 The procedure of Example 1 can be repeated replacing piperazine in Example 1(e) with 3-hydroxypyrrolidine to obtain 1-phenyl-6,8-difluoro-1,4-dihydro-4-oxo-7-(3-hydroxy-1-pyrrolidinyl)-quinoline-3-carboxylic acid.
- Example 1 The procedure of Example 1 is repeated replacing piperazine in Example 1 (e) with piperidine to obtain 1-phenyl-6,8-difluoro-1,4-dihydro-4-oxo-7-(1-piperidinyl)-quinoline-3-carboxylic acid.
- Example 1 In the described fashion as Example 1, replacing piperazine in Example 1 (e) with morpholine, one can obtain 1-phenyl-6,8-difluoro-1,4-dihydro-4-oxo-7-(4-morpholinyl)-quinoline-3-carboxylic acid in good yield.
- Example 1 The procedure of Example 1 can be repeated replacing piperazine in Example 1(e) with thiomorpholine to obtain 1-phenyl-6,8-difluoro-1,4-dihydro-4-oxo-7-(4-thiomorpholinyl)-quinoline-3-carboxylic acid.
- Example 1 In the described fashion as Example 1, replacing piperazinyl in Example 1(e) with 2,6-dimethylpiperazine, one obtains 1-phenyl-6,8-difluoro-1,4-dihydro-4-oxo-7-(3,5-dimethyl-1-piperazinyl)-quinoline-3-carboxylic acid and its hydrochloride salt.
- Example 1 The procedure of Example 1 is repeated replacing piperazine in Example 1(e) with homopiperazine to obtain I-phenyl-6,8-difluoro-4-dihydro-4-oxo-7-(1-homopiperazinyl)-quinoline-3-carboxylic acid and its hydrochloride salt.
- Example 1 replacing piperazine in Example 1(e) with dimethylamine, one can obtain 1-phenyl-6,8-difluoro-1,4-dihydro-4-oxo-7-(dimethylamino)-quinoline-3-carboxylic acid.
- Example 1 The procedure of Example 1 can be repeated replacing piperazine in Example 1(e) with N-2-hydroxyethylamine to obtain 1-phenyl-6,8-difluoro-1,4-dihydro-4-oxo-7-(N-2-hydroxy-ethylamino)-quinoline-3-carboxylic acid.
- Example 1 In the described fashion as Example 1, replacing piperazine in Example 1(e) with hydrazine, one can obtain 1-phenyl-6,8-difluoro-1,4-dihydro-4-oxo-7-(hydrazyl)-quinoline-3-carboxylic acid and its hydrochloride salt.
- Example 1 The procedure of Example 1 can be repeated, replacing piperazine in Example 1(e) with 1,1-dimethylhydrazine to obtain 1-phenyl-6,8-difluoro-1,4-dihydro-4-oxo-7-(2,2-dimethyl-hydrazyl)-quinoline-3-carboxylic acid and its hydrochloride salt.
- Example 1(e) replacing the acid with the acid of the product of Example 15(b) and also replacing piperazine with an appropriate amine such as n-methylpiperazine, pyrrolidine, 3-hydroxypyrrolidine, 3-acetaminopyrrolidine, piperidine, morpholine, thiomorpholine, 2,6-dimethylpiperazine, homopiperazine, diethylamine and 2,2-dimethylhydrazine, one can obtain the following compounds:
- Example 16(d) the compound of Example 16(d) can give 1-p-fluorophenyl-6,8-diffuoro-1,4-dihydro-4-oxo-7-(3-amino-1-pyrrolidinyl)-quinoline-3-carboxylic acid.
- Example 1(e) replacing the acid with the acid of the product of Example 18(b) and also replacing piperazine with an appropriate amine such as N-methylpiperazine, pyrrolidine, 3-hydroxy pyrrolidine, 3-acetamidopyrrolidine, piperidine, morpholine, thiomorpholine, 2,6-dimethylpiperazine, homopiperazine, dimethylamine and 2,2-dimethylhydrazine, one can obtain the following compounds:
- Example 18(d) the compound of Example 18(d) can give 1-p-hydroxyphenyl-6,8-difluoro-1,4-dihydro-4-oxo-7-(3-amino-1-pyrrolidinyl)-quinoline-3-carboxylic acid.
- Example 1(a-d) replacing aniline with an appropriate amine (R-NH 2 ), one can obtain the additional 1-substituted 6,7,8-trifluoro-1,4-dihydro-4-oxo-quinoline-3-carboxylic acid as listed in Table I.
- Example 1 (e) replacing the acid with the acid of the compounds listed in Table 1 of Example 21 and also replacing piperazine with an appropriate amine such as N-methylpiperazine, pyrrolidine, 3-hydroxypyrrolidine, 3-acetamidopyrrolidine, 3-dimethylaminopyrrolidine, piperidine, morpholine, thiomorpholine, 2,6-dimethylpiperazine, homopiperazine, dimethylamine and 2,2-dimethylhydrazine, one can obtain the following additional compounds as summarized in Table II.
- an appropriate amine such as N-methylpiperazine, pyrrolidine, 3-hydroxypyrrolidine, 3-acetamidopyrrolidine, 3-dimethylaminopyrrolidine, piperidine, morpholine, thiomorpholine, 2,6-dimethylpiperazine, homopiperazine, dimethylamine and 2,2-dimethylhydrazine
- Example 5(b) the compounds 11 and 12 in Example 22 can be converted to:
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Claims (20)
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US574225 | 1975-05-05 | ||
US57422584A | 1984-01-26 | 1984-01-26 | |
US57411984A | 1984-01-26 | 1984-01-26 | |
US57422484A | 1984-01-26 | 1984-01-26 | |
US574224 | 1984-01-26 | ||
US574119 | 1984-01-26 |
Publications (2)
Publication Number | Publication Date |
---|---|
EP0154780A1 EP0154780A1 (fr) | 1985-09-18 |
EP0154780B1 true EP0154780B1 (fr) | 1990-04-11 |
Family
ID=27416170
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP85100767A Expired - Lifetime EP0154780B1 (fr) | 1984-01-26 | 1985-01-25 | Composés antibactériens quinoléiques |
Country Status (2)
Country | Link |
---|---|
EP (1) | EP0154780B1 (fr) |
DE (1) | DE3577089D1 (fr) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001036408A1 (fr) * | 1999-11-15 | 2001-05-25 | New Pharma Research Sweden Ab | Composes antibacteriens et antiparasitaires |
US9012474B2 (en) | 2006-02-17 | 2015-04-21 | Idexx Laboratories Inc. | Fluoroquinolone compositions |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0181521A1 (fr) * | 1984-10-19 | 1986-05-21 | Otsuka Pharmaceutical Co., Ltd. | Composés d'acide 1-phényl substitué-4-oxo-3-quinoléine carboxylique |
US4755513A (en) * | 1985-01-30 | 1988-07-05 | Otsuka Pharmaceutical Company, Limited | Antimicrobial 1-substituted phenyl-4-oxoquinoline-3-carboxylic acid compounds |
DE3517535A1 (de) * | 1985-05-15 | 1986-11-20 | Bayer Ag, 5090 Leverkusen | 1-aryl-4-chinolon-3-carbonsaeuren |
JPH0633256B2 (ja) * | 1985-12-20 | 1994-05-02 | 大塚製薬株式会社 | キノリンカルボン酸誘導体 |
NO871333L (no) * | 1986-03-31 | 1987-10-01 | Sankyo Co | Kinolin-3-karboksylsyrederivater, fremgangsmaate til fremstilling og anvendelse derav. |
GB8612137D0 (en) * | 1986-05-19 | 1986-06-25 | Fujisawa Pharmaceutical Co | Quinolone compounds |
US4762845A (en) * | 1986-05-21 | 1988-08-09 | Abbott Laboratories | 7-(3-Substituted imino-1-pyrrolidinyl)-quinolone-3-carboxylic acids |
US4771055A (en) * | 1986-07-28 | 1988-09-13 | Warner-Lambert Company | 7-[[3-(aminomethyl)-3-alkyl]-1-pyrrolidinyl]-quinoline-carboxylic acids |
DE3934082A1 (de) * | 1989-10-12 | 1991-04-18 | Bayer Ag | Chinoloncarbonsaeurederivate, verfahren zu ihrer herstellung sowie ihre verwendung als antivirale mittel |
FR2655545B1 (fr) * | 1989-12-11 | 1994-06-10 | Rhone Poulenc Sante | Nouvelle application therapeutique des derives des fluoroquinolones. |
DE4120646A1 (de) * | 1991-06-22 | 1992-12-24 | Bayer Ag | 7-isoindolinyl-chinolon- und naphthyridoncarbonsaeure-derivate |
DE4121214A1 (de) * | 1991-06-27 | 1993-01-14 | Bayer Ag | 7-azaisoindolinyl-chinolon- und -naphthyridoncarbonsaeure-derivate |
US5532239A (en) * | 1993-08-02 | 1996-07-02 | Assistance Publique - Hopitaux De Paris | Therapeutic application of fluoroquinolone derivatives |
CN1053668C (zh) * | 1994-06-14 | 2000-06-21 | 大日本制药株式会社 | 新型化合物及其制法和抗肿瘤剂 |
EP1313708A1 (fr) * | 2000-08-29 | 2003-05-28 | Chiron Corporation | Composes de quinoline antibacteriens et procedes d'utilisation de ceux-ci |
US7973022B2 (en) | 2006-02-17 | 2011-07-05 | Idexx Laboratories, Inc. | Fluoroquinolone carboxylic acid salt compositions |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1147336A (en) * | 1965-06-14 | 1969-04-02 | Lilly Industries Ltd | Quinoline-3-carboxylic acid derivatives |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3506667A (en) * | 1969-05-01 | 1970-04-14 | Warner Lambert Pharmaceutical | Furo quinoline carboxylates |
US4017622A (en) * | 1972-12-18 | 1977-04-12 | Dainippon Pharmaceutical Co., Ltd. | Piperazine derivatives |
CA1175836A (fr) * | 1977-09-20 | 1984-10-09 | Marcel Pesson | Production de derives de l'acide 1,4- dihydroquinoline-3-carboxylique |
DE2808070A1 (de) * | 1978-02-24 | 1979-08-30 | Bayer Ag | Verfahren zur herstellung von 4-pyridon-3-carbonsaeuren und/oder deren derivaten |
JPS57145862A (en) * | 1981-03-06 | 1982-09-09 | Kyorin Pharmaceut Co Ltd | Quinolinecarboxylic acid derivative |
DE3318145A1 (de) * | 1983-05-18 | 1984-11-22 | Bayer Ag, 5090 Leverkusen | 7-amino-1-cyclopropyl-6,8-difluor-1,4-dihydro-4-oxo-3-chinolincarbonsaeuren, verfahren zu ihrer herstellung sowie diese enthaltende antibakterielle mittel |
NZ208470A (en) * | 1983-07-18 | 1988-06-30 | Abbott Lab | 6-fluoro-1,4-dihydro-4-oxo-quinoline-3-carboxylic acid derivatives and antibacterial compositions containing such |
-
1985
- 1985-01-25 EP EP85100767A patent/EP0154780B1/fr not_active Expired - Lifetime
- 1985-01-25 DE DE8585100767T patent/DE3577089D1/de not_active Expired - Fee Related
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1147336A (en) * | 1965-06-14 | 1969-04-02 | Lilly Industries Ltd | Quinoline-3-carboxylic acid derivatives |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001036408A1 (fr) * | 1999-11-15 | 2001-05-25 | New Pharma Research Sweden Ab | Composes antibacteriens et antiparasitaires |
US9012474B2 (en) | 2006-02-17 | 2015-04-21 | Idexx Laboratories Inc. | Fluoroquinolone compositions |
Also Published As
Publication number | Publication date |
---|---|
EP0154780A1 (fr) | 1985-09-18 |
DE3577089D1 (de) | 1990-05-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US4730000A (en) | Quinoline antibacterial compounds | |
EP0154780B1 (fr) | Composés antibactériens quinoléiques | |
EP0131839B1 (fr) | Composés quinoléiniques antibactériens | |
US5051418A (en) | Antibacterial 8-cyano-1-cyclopropyl-1,4-dihydro-4-oxo-3-quinolinecarboxylic acids | |
US4556658A (en) | 7-Amino-1-cyclopropyl-6,8-difluoro-1,4-dihydro-4-oxo-quinoline-3-carboxylic acids and antibacterial agents containing these compounds | |
DK157997B (da) | 6-fluor-1,4-dihydro-4-oxo-7-substituerede piperazinylquinolin-3-carboxylsyrederivater og deres farmakologisk acceptable salte samt farmaceutiske sammensaetninger til brug ved behandling af bakterielle sygdomme | |
EP0160284B1 (fr) | Composés de quino-benzoxazine antibactériens | |
JPS60204765A (ja) | 1,7―ジアミノ―1,4―ジヒドロ―4―オキソ―3―(アザ)キノリン―カルボン酸及びその製造法 | |
US4616019A (en) | Naphthyridine antibacterial compounds | |
EP0153580B2 (fr) | Composés antibactériaux de naphthyridine | |
US4774246A (en) | Quinoline antibacterial compounds | |
US4607032A (en) | Quino-benoxazine antibacterial compounds | |
US4533663A (en) | Quino-benzothiazine antibacterial compounds | |
WO1990006307A2 (fr) | Composes de quinolone antibacteriens | |
US4540694A (en) | 1-Pyridine substituted quino-benoxazines and antibacterial use | |
EP0162333B1 (fr) | Composés antibactériens dérivés de quino-benzothiazine | |
US4528285A (en) | Methylenedioxy quino-benzothiazine derivatives | |
IE872444L (en) | Pyrido-benzoxadiazine derivatives | |
US4542133A (en) | Methylenedioxy quino-benoxazine derivatives and antibacterial use | |
US4720495A (en) | Benzo[ij]quinolizine-2-carboxylic acids useful for treating bacterial infection | |
US4529725A (en) | 1-Pyridine substituted quino-benzothiazine | |
US4889857A (en) | Quinolonecarboxylic acid compounds and pharmaceutical use thereof | |
CA1337600C (fr) | Composes antibacteriens a base de quinolone | |
JPH0568466B2 (fr) | ||
CA1340782C (fr) | Composes antibacteriens a base de naphtyridone |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
AK | Designated contracting states |
Designated state(s): BE CH DE FR GB IT LI NL SE |
|
17P | Request for examination filed |
Effective date: 19860314 |
|
17Q | First examination report despatched |
Effective date: 19871223 |
|
GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
AK | Designated contracting states |
Kind code of ref document: B1 Designated state(s): BE CH DE FR GB IT LI NL SE |
|
ET | Fr: translation filed | ||
REF | Corresponds to: |
Ref document number: 3577089 Country of ref document: DE Date of ref document: 19900517 |
|
ITF | It: translation for a ep patent filed |
Owner name: MODIANO & ASSOCIATI S.R.L. |
|
PLBE | No opposition filed within time limit |
Free format text: ORIGINAL CODE: 0009261 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT |
|
26N | No opposition filed | ||
ITTA | It: last paid annual fee | ||
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: SE Payment date: 19941215 Year of fee payment: 11 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: GB Payment date: 19941219 Year of fee payment: 11 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: FR Payment date: 19950113 Year of fee payment: 11 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: DE Payment date: 19950125 Year of fee payment: 11 |
|
EAL | Se: european patent in force in sweden |
Ref document number: 85100767.4 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: NL Payment date: 19950131 Year of fee payment: 11 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: BE Payment date: 19950202 Year of fee payment: 11 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: CH Payment date: 19950404 Year of fee payment: 11 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: GB Effective date: 19960125 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SE Effective date: 19960126 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LI Effective date: 19960131 Ref country code: CH Effective date: 19960131 Ref country code: BE Effective date: 19960131 |
|
BERE | Be: lapsed |
Owner name: ABBOTT LABORATORIES Effective date: 19960131 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: NL Effective date: 19960801 |
|
GBPC | Gb: european patent ceased through non-payment of renewal fee |
Effective date: 19960125 |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: PL |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: FR Effective date: 19960930 |
|
NLV4 | Nl: lapsed or anulled due to non-payment of the annual fee |
Effective date: 19960801 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: DE Effective date: 19961001 |
|
EUG | Se: european patent has lapsed |
Ref document number: 85100767.4 |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: ST |